Abstract 3821: Real world outcomes among patients with newly diagnosed acute myeloid leukemia
Real world outcomes among patients with newly diagnosed acute myeloid leukemia
Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH)
Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)
TREATMENT PATTERNS AND REAL-WORLD OUTCOMES OF MOLECULAR SUBGROUPS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING FRONTLINE VENETOCLAX-BASED THERAPY
REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data
Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)
Agreement Between Real-World Physician Response Assessment & the 2017 European Leukemianet (ELN) Criteria in Acute Myeloid Leukemia (AML): A Comparative Analysis
